ASCO 2026: biomarkers of response to Reqorsa gene therapy for lung cancer https://ymaho.com/asco-2026-biomarkers-of-response-to-reqorsa-gene-therapy-for-lung-cancer
Reqorsa gene therapy identified TROP2 and PTEN biomarkers for lung cancer prognosis. Learn ASCO 2026 data and prospects for treating NSCLC and SCLC.
AI test for bladder cancer: FDA breakthrough device https://ymaho.com/ai-test-for-bladder-cancer-fda-breakthrough-device
FDA has granted breakthrough device designation to an AI tool for predicting bladder cancer prognosis. Learn how Vesta by Valar Labs is changing oncourology and treatment economics.
Tzield approved for children from 1 year: delaying type 1 diabetes https://ymaho.com/tzield-approved-for-children-from-1-year-delaying-type-1-diabetes
FDA expanded indications for teplizumab to children from one year. First drug capable of delaying diabetes for years at the preclinical stage. Learn how infusions change the prognosis for infants.
Hantavirus outbreak on a cruise ship: WHO analysis and risks https://ymaho.com/hantavirus-outbreak-on-a-cruise-ship-who-analysis-and-risks
WHO reported an outbreak of hantavirus ANDV on the MV Hondius ship with 7 cases and 3 deaths. Learn about the timeline, transmission risks, and prognosis. Read the full analysis.
Dembele injured before Champions League final: PSG lost to Paris https://lrivo.com/dembele-injured-before-champions-league-final-psg-lost-to-paris
Ousmane Dembele injured in derby with Paris 2 weeks before Champions League final. Find out match details and recovery prognosis. Read now!
Bulevirtide (Hepcludex®): FDA approval for hepatitis D https://ymaho.com/bulevirtide-hepcludex-fda-approval-for-hepatitis-d
FDA approved the first drug for chronic hepatitis D — bulevirtide. Mechanism, doses, risks, price, and prognosis. Find out who is suitable for therapy.
Gene therapy AB-1009 for Pompe disease: clinical trial https://ymaho.com/gene-therapy-ab-1009-for-pompe-disease-clinical-trial
A clinical trial of gene therapy AB-1009 for late-onset Pompe disease (LOPD) has begun. Phase 1 analysis, mechanism of action, risks, and prognosis. Learn more.
FDA approved bulevirtide (Hepcludex): treatment of hepatitis delta in the USA https://ymaho.com/fda-approved-bulevirtide-hepcludex-treatment-of-hepatitis-delta-in-the-usa
FDA approved the first US drug for hepatitis delta — bulevirtide (Hepcludex). Learn about dosage, risks, price, and prognosis. Read the full analysis.
Targeted therapy for Usher syndrome 1B: new data on AAVB-081 https://ymaho.com/targeted-therapy-for-usher-syndrome-1b-new-data-on-aavb-081
Interim data from phase 1/2 gene therapy AAVB-081 for Usher syndrome 1B: safety, efficacy, and prognosis. Learn about the dual AAV vector and treatment prospects.
Immunotherapy for BRAF Colorectal Cancer: New Data from Nature Medicine https://ymaho.com/immunotherapy-for-braf-colorectal-cancer-new-data-from-nature-medicine
Analysis of the efficacy of encorafenib and binimetinib combination in BRAF-mutant colorectal cancer. Results, limitations, prognosis, and side effects. Read more.